


Basics and Clinical Applications of Drug Disposition in Special Populations

Edited by
Seth Kwabena Amponsah
Yashwant V. Pathak



WILEY

Basics and Clinical Applications of Drug Disposition in Special Populations

Basics and Clinical Applications of Drug Disposition in Special Populations

Edited by

*Seth Kwabena Amponsah
University of Ghana Medical School
Accra, Ghana*

*Yashwant V. Pathak
USF Health Taneja College of Pharmacy
Tampa, Florida, USA*

WILEY

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.
Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

The manufacturer's authorized representative according to the EU General Product Safety Regulation is Wiley-VCH GmbH, Boschstr. 12, 69469 Weinheim, Germany,
e-mail: Product_Safety@wiley.com.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data Applied for:

Hardback ISBN: 9781394251285

Cover Design: Wiley

Cover Image: Courtesy of Seth Kwabena Amponsah and Yashwant V. Pathak

Set in 9.5/12.5pt STIX Two Text by Straive, Pondicherry, India

Dedication

I dedicate this book to my academic mentors, Professor Kwasi Agyei Bugyei and Professor George Obeng Adjei. I also dedicate this book to a very good friend, Dr. Enoch Narh Kudjorjdie.

—*Seth Kwabena Amponsah*

This book is dedicated to the elders and people of ancient traditions and cultures who believe in working for humanity.

—*Yashwant V. Pathak*

Contents

About the Editors	xxi
List of Contributors	xxiii
Foreword	xxix
Preface	xxx

1 Pharmacokinetic Principles and Concepts: An Overview 1

Seth K. Amponsah and Yahwant V. Pathak

1.1	Introduction	1
1.2	Pharmacokinetic Parameters	2
1.2.1	Absorption	2
1.2.2	Distribution	3
1.2.3	Metabolism	4
1.2.4	Excretion	5
1.3	Pharmacokinetic Models	5
1.4	Applications	6
1.5	Conclusion	7
	References	7

2 Model-Based Pharmacokinetic Approaches 11

Manish P. Patel, Kashyap M. Patel, Shakil Z. Vhora, Anuradha K. Gajjar, Jayvadan K. Patel, and Amitkumar K. Patel

2.1	Introduction	11
2.1.1	Importance of PK	12
2.1.2	Overview of Model-Based Approaches	13
2.2	Basics of Pharmacokinetics	14
2.2.1	Key Pharmacokinetic Parameters	14
2.2.1.1	Absorption	14
2.2.1.2	Key Parameter	14
2.2.1.3	Distribution	14
2.2.1.4	Key Parameter	15

2.2.1.5	Metabolism	15
2.2.1.6	Key Parameter	15
2.2.1.7	Excretion	15
2.2.1.8	Key Parameter	15
2.2.2	Differences Between Traditional and Model-Based Pharmacokinetic Approaches	16
2.3	Pharmacokinetic (PK) Models	17
2.3.1	Introduction	17
2.3.2	Compartment Modeling	18
2.3.2.1	One-Compartment Model	21
2.3.2.2	Multi-Compartment Model	21
2.3.2.3	Two-Compartment Model	24
2.3.3	Population PK Model	25
2.3.4	Physiologically Based PK (PBPK) Model	26
2.4	Model Development and Validation	27
2.4.1	Data Requirements for Model Development	27
2.4.2	Data Requirements for Model Validation	29
2.4.3	Steps in Model Building (E.g., Model Selection and Parameter Estimation)	29
2.5	Applications of Model-Based Approaches	31
2.5.1	Dose Optimization	31
2.5.2	Predicting Drug Interactions	32
2.5.3	Drug Tailoring in Special Populations (E.g., Pediatrics, Geriatrics, and Renal Impairment)	33
2.5.4	Translational PK from Preclinical to Clinical Settings	34
2.6	Modeling in Special Populations	36
2.6.1	Challenges and Considerations	36
2.6.1.1	Challenges in PK Modeling	36
2.6.1.2	Considerations in PK Modeling	36
2.7	Software and Tools for PK Modeling	37
2.7.1	Gastroplus™	38
2.7.2	Berkeley Madonna	38
2.7.3	MATLAB	38
2.7.4	PK-Sim®	39
2.7.5	Simcyp®	39
2.7.6	Auxiliary PBPK Modeling Software	39
2.7.6.1	Julia	39
2.7.6.2	NONMEM	39
2.7.6.3	Phoenix WinNonlin	40
2.7.6.4	GraphPad Prism	40
2.7.6.5	Minitab	40
2.7.6.6	PlotDigitizer	40

2.7.6.7	GNU MCSim	40
2.7.6.8	WebPlotDigitizer	40
2.8	Regulatory Perspectives of PK Modeling	40
2.9	Future Directions of PK Modeling	43
2.10	Conclusion	43
	Abbreviations	44
	References	45

3 Physiologically Based Pharmacokinetic Modeling 53

Mahesh P. More and Rahul S. Tade

3.1	Introduction	53
3.2	Significance of PBPK Modeling	56
3.3	Principles for the Development of PBPK for Special Populations	57
3.4	Data Integration for Special Populations	57
3.4.1	Demographic Data	58
3.4.2	Physiological Consideration	58
3.4.3	Ontogeny	58
3.4.4	Age and Maturation Changes	59
3.4.5	Steady State Volume of Distribution (Vdss)	59
3.5	Applications of PBPK Modeling	60
3.5.1	Dose Optimization/Regimen/Selection	60
3.5.2	Dose Individualization/Precision Dosing	61
3.5.3	Biopharmaceutics	62
3.6	Regulatory Applications/Pre–Post Market Utilization	62
3.7	Case Studies	64
3.7.1	Simulation Application	64
3.7.2	Successful Applications	67
3.8	Lessons Learned	68
3.9	Conclusion	68
	References	70

4 Therapeutic Drug Monitoring in Special Populations 75

James A. Akingbasote, Sandra K. Szlapinski, Elora Hilmas, Kyle Weston, Yelena Wu, and Alexandra Burton

4.1	Introduction	75
4.2	Pediatrics	76
4.2.1	Importance of TDM in Pediatrics	76
4.2.2	Pharmacokinetic Differences in Pediatric Patients	77
4.2.3	Drug Absorption in the Pediatric Population	77
4.2.4	Drug Distribution in the Pediatric Population	78
4.2.5	Drug Metabolism and Elimination in the Pediatric Population	79
4.3	TDM Practices in Pediatrics	79

4.3.1	Vancomycin	80
4.3.2	Aminoglycosides	81
4.3.3	Ganciclovir/Valganciclovir	82
4.3.4	Antiepileptic Drugs (AEDs)	83
4.3.5	Enoxaparin	84
4.4	Conclusion	85
4.5	Pregnancy	85
4.5.1	Physiological Adaptations in Pregnancy	85
4.5.2	Current State of Clinical Practice of TDM in Pregnancy	87
4.5.3	TDM in Pregnancy	89
4.5.3.1	Antiepileptics	89
4.5.3.2	Antidepressants	90
4.5.3.3	Antiretroviral Drugs	91
4.5.3.4	Immunomodulatory Drugs	93
4.5.4	Challenges in the Implementation of TDM in the Pregnant Population	94
4.6	The Elderly	95
4.6.1	Physiological Changes in the Elderly	95
4.6.2	Effect of Aging on Drug Pharmacokinetics	95
4.6.3	Application of TDM in the Elderly	97
4.6.3.1	Cardiac Glycosides	98
4.6.3.2	Serotonin–Norepinephrine Reuptake Inhibitor (SNRI)	98
4.6.3.3	Anticoagulants	99
4.6.3.4	Benzodiazepines	99
4.7	Conclusion	101
4.8	Hepatic and Renal Impairments	101
4.8.1	Hepatic Impairment	102
4.8.2	TDM in Patients with Hepatic Impairment	104
4.8.2.1	Meropenem	105
4.8.2.2	Metoprolol	105
4.8.2.3	Midazolam	106
4.8.3	Renal Impairment	107
4.8.4	Prerenal Disease	109
4.8.5	Intrinsic Renal Vascular Disease	109
4.8.6	Intrinsic Glomerular Disease (Nephritic or Nephrotic)	109
4.8.7	TDM in Renal Impairment	109
4.8.7.1	Vancomycin	111
4.8.7.2	Metformin	111
4.9	Conclusion	112
4.10	Overall Conclusion and Future Direction	112
	Acknowledgment	113
	References	114

5 Optimization of Drug Dosing Regimen 133

Vivek Patel, Kartik Hariharan, Dhruv Shah, Arindam Halder, Ajay J. Khopade, Amitkumar K. Patel, and Jayvadan K. Patel

- 5.1 Introduction 133
- 5.2 Dosing Regimen Optimization Approaches and Strategies 134
 - 5.2.1 Models Used for Dosing Regimen Selection 134
 - 5.2.1.1 Pharmacometric Models 134
 - 5.2.1.2 PK Models 135
 - 5.2.1.3 Empirical Dose–Response Models 136
 - 5.2.1.4 Multiple Comparison Procedures Models (MCP-Mod) 136
 - 5.2.1.5 Model Averaging 137
 - 5.2.2 Role of Patient Characteristics in Dose Selection 137
 - 5.2.2.1 Phenotype-Guided Dosing 137
 - 5.2.2.2 Genotype-Guided Drug Dosing 138
 - 5.2.3 Therapeutic Drug Monitoring (TDM) 138
- 5.3 Dosing Regimen in Special Populations 139
 - 5.3.1 Dosing Regimen in Cancer Patients 139
 - 5.3.1.1 Metronomic Chemotherapy 140
 - 5.3.2 Dosing Regimen for Patients on Antimicrobial Therapy 142
 - 5.3.2.1 Antimicrobial Stewardship Strategy 145
 - 5.3.2.2 Mathematical Models for Optimizing Antimicrobial Therapy 146
 - 5.3.2.3 Antimicrobial Dosing Strategies During CRRT 147
 - 5.3.2.4 Methods for Enhancing Dosing of Antimicrobials via Nebulization 149
 - 5.3.3 Dosing Regimen in Pediatric Patients 149
 - 5.3.3.1 Physiological Differences Between Pediatric and Adult Patients 149
 - 5.3.3.2 Application of MIDD in Pediatric Dose Selection 149
 - 5.3.3.3 Scaling from Adults to Pediatric Patients 150
 - 5.3.3.4 Scaling from Animals to Pediatric Patients 150
 - 5.3.3.5 Integrating Mechanistic Models in Neonates and Infants 150
 - 5.3.3.6 Dose Optimization in Neonates and Infants 151
- 5.4 Conclusion 151
- References 152

6 Artificial Intelligence in Drug Development 161

Surovi Saikia, Aparna Anandan, Unais Annenkottil, Vishnu P. Athilingam, Partha P. Kalita, and Viswanadha V. Padma

- 6.1 Introduction 161
- 6.2 Application of AI in Drug Design 162
 - 6.2.1 Target Identification and Validation 162
 - 6.2.2 Drug Candidate Design and Optimization 162
 - 6.2.3 Virtual Screening and Molecular Docking 163

- 6.2.4 Synthesis Planning 163
- 6.2.5 Predicting Drug Toxicity and Pharmacokinetics 163
- 6.2.6 Personalized Medicine 163
- 6.3 AI Use in Drug Formulation 163
- 6.4 Drug Release Characterization Using AI 164
- 6.5 AI-Based Dose/Dosing Regimen 165
- 6.6 Dissolution Rate Predictions with AI 166
- 6.7 Clinical End-Point Evaluation with AI 166
- 6.8 AI in Prediction of Fate of Drugs Administered Via Mucosal, Transdermal, and Parenteral Routes 167
- 6.9 AI-Integrated Mechanistic Modeling Platform for Drug Delivery and Monitoring 169
- 6.10 AI-Based Tools for Metabolism and Clearance Prediction 169
- 6.11 Limitations of Existing Tools 171
- 6.12 Conclusions 171
- 6.13 Conflict of Interest 171
- Acknowledgments 171
- References 172

7 Drug Disposition in Neonates and Infants 179

David Gyamfi, Emmanuel B. Amofo, Awo A. Kwapong, Mansa Fredua-Agyeman, and Seth K. Amponsah

- 7.1 Introduction 179
- 7.2 Drug Absorption in Neonates and Infants 180
- 7.3 Drug Distribution in Neonates and Infants 182
- 7.4 Hepatic Metabolism of Drugs in Neonates and Infants 185
- 7.4.1 Phase I Metabolism 185
- 7.4.2 Phase II Metabolism 187
- 7.5 Drug Excretion in Neonates and Infants 188
- 7.6 Pharmacodynamics in Neonates and Infants 190
- 7.7 Age-Related Dosing Regimen in Neonates and Infants 190
- 7.8 Conclusion 192
- References 193

8 Drug Disposition in Adolescents 203

Aparoop Das, Kalyani Pathak, Riya Saikia, Manash P. Pathak, Urvashree Gogoi, Jon J. Sahariah, Dibyajyoti Das, Md Ariful Islam, and Pallab Pramanik

- 8.1 Introduction 203
- 8.2 Physiological Considerations in Adolescents 206
- 8.2.1 Organ Development: Liver and Kidney Maturation 206

8.2.2	Variations in Body Composition	208
8.2.3	Hormonal Changes	208
8.2.3.1	Males	208
8.2.3.2	Females	209
8.2.4	Other Physiological Changes	210
8.3	Medication Adherence Challenges in Adolescents	211
8.4	Psychological Development on Drug Disposition	212
8.5	Risk-Taking behaviors and Their Implications on Medication Use	213
8.6	Drug Use Among Adolescents	215
8.6.1	Acetaminophen Use in Adolescents	215
8.6.2	Antidepressant Use in Adolescents	215
8.6.3	Drugs for ADHD	216
8.7	Pharmacokinetic Variability in Adolescents Drug Examples	217
8.7.1	Acetaminophen	217
8.7.2	Theophylline	217
8.7.3	Antidepressants	218
8.7.4	Drugs for ADHD	218
8.8	Legal and Ethical Considerations	219
8.8.1	Consent and Confidentiality in Adolescent Healthcare	219
8.8.2	Involving Adolescents in Treatment Decisions	220
8.8.3	Regulatory Aspects of Adolescents Drug Prescribing	221
8.9	Conclusion	221
	References	222

9 Drug Disposition in Pregnancy 229

Jacob Treanor, Stefanos Belavilas, Dominique Cook, Justin Cole, Amruta Potdar, and Charles Preuss

9.1	Introduction	229
9.2	Physiological Changes in Pregnancy	230
9.2.1	Changes in Absorption	231
9.2.2	Changes in Distribution and Free Medication	231
9.2.3	Changes in Cytochrome Metabolism	233
9.2.4	Changes in Renal Excretion	233
9.2.5	General Considerations in Drug Dosing with Pregnancy	234
9.3	Placental Drug Disposition	234
9.3.1	Placental Barrier Anatomy and Physiology	235
9.3.2	Placental Transport Mechanisms	237
9.3.3	Methods of Study for Placental Drug Transfer	238
9.4	Drug Classification in Pregnancy	239
9.5	Pharmacokinetic (PK) Modeling	241
9.6	Physiologically Based Pharmacokinetic (PBPK) Modeling	242

9.7	Limitations in PK and PBPK Models	244
9.8	PBPK Model Variables	244
9.9	Determining Treatment During Pregnancy	245
9.10	Fetal Blood Flow and Drug Processing	245
9.10.1	Hepatic and Renal Processing	246
9.10.2	Embryonic Staging	248
9.11	Teratogens	249
9.11.1	Thalidomide	250
9.11.2	Alcohol	251
9.11.3	Smoking and E-cigarettes	251
9.11.4	Caffeine	252
9.11.5	Antibiotics	253
9.11.6	Retinoids	254
9.12	Conclusion	257
	Abbreviations	257
	References	258

10 Drug Disposition in Obesity 265

Seema Kohli and Ankita A. Singh

10.1	Introduction	265
10.2	Index of Obesity	265
10.3	Pathogenesis of Obesity/Overweight	266
10.4	Drug Disposition in Obesity	267
10.4.1	Absorption	267
10.4.2	Distribution	268
10.4.3	Metabolism	268
10.4.4	Renal Excretion	270
10.5	Drug Dose Calculations in Obese Patients	270
10.5.1	Volume of Distribution (Vd)	270
10.5.2	Drug Clearance	271
10.5.3	Body Size Description	271
10.5.4	Drug Dose Calculation	272
10.6	Disposition of Drugs in Obesity	273
10.6.1	Volatile Agents	273
10.6.2	Thiopental	274
10.6.3	Propofol	274
10.6.4	Midazolam	274
10.6.5	Acetaminophen	274
10.6.6	Opioids	275
10.6.7	Unfractionated Heparin	275
10.6.8	Cephazolin	275

10.6.9	Enoxaparin	275
10.7	Conclusion	276
	References	276

11 Drug Disposition in Critical Care Patients 281

Chinenye E. Muolokwu, Benjamin Tagoe, Michael M. Attah, and Seth K. Amponsah

11.1	Introduction	281
11.2	Pharmacokinetic Considerations in Critical Care Patients	282
11.2.1	Drug Absorption Considerations in Critical Care Patients	282
11.2.2	Drug Distribution Considerations in Critical Care Patients	283
11.2.3	Drug Metabolism Considerations in Critical Care Patients	284
11.2.4	Drug Excretion Considerations in Critical Care Patients	285
11.3	Dosing Algorithms for Commonly Administered Drugs in Critical Care Patients	286
11.3.1	Antibacterial and Antifungal Agents	286
11.3.1.1	Aminoglycosides	287
11.3.1.2	β -Lactam Antibiotics	288
11.3.1.3	Fluoroquinolones	288
11.3.1.4	Oxazolidinones	289
11.3.1.5	Antifungal Agents	289
11.3.2	Inotropes	291
11.3.3	Antiviral Drugs	292
11.3.4	Narcotic Analgesics	292
11.3.4.1	Morphine and Pethidine	292
11.3.4.2	Fentanyl and Derivatives	293
11.3.5	Sedatives and Hypnotics	293
11.3.5.1	Midazolam	294
11.3.5.2	Lorazepam	295
11.3.6	Neuromuscular Blockers	295
11.4	Conclusion	297
	References	297

12 Drug Disposition in Renal Insufficiency 305

Sarah Nestler, Deborah Liaw, Gabriella Blanco, Rana Hanna, Ellen Si, and Charles Preuss

12.1	Renal Physiology	305
12.1.1	General Anatomical Structure	305
12.1.2	General Function of the Nephron	306
12.1.3	Water Regulation	306
12.1.4	Glomerular Filtration Rate (GFR)	307

12.1.5	Acid–Base Regulation	307
12.2	Glomerular Filtration Rate	307
12.3	Acute Kidney Injury	308
12.3.1	Diagnostic Criteria and Classification	308
12.3.2	Causes of AKI	310
12.3.3	Prerenal	310
12.3.4	Intrinsic	310
12.3.5	Postrenal	311
12.4	Chronic Kidney Disease	311
12.4.1	Diagnostic Criteria and Classification	311
12.4.2	Causes of Chronic Kidney Disease	312
12.5	Medication Dosing Modifications	313
12.5.1	Medication Dosing in Patients with CKD	313
12.5.2	Medications to Treat CKD-Induced HTN and Medications to Avoid in CKD	314
12.5.2.1	Antihypertensives	314
12.5.2.2	Hypoglycemics	316
12.5.2.3	Antimicrobials	317
12.5.2.4	Statins	321
12.5.2.5	NSAIDs	322
12.5.2.6	Analgesics	322
12.6	Epidemiology and Outcomes of Patients with CKD	323
	References	324

13 Drug Disposition in Hepatic Insufficiency 327

Fried A. Abilba, Jacob A. Ayembilla, and Raphael N. Alolga

13.1	Introduction	327
13.2	The Spectrum of Liver Diseases	328
13.3	Liver Function and Drug Metabolism	330
13.3.1	Impact of Hepatic Insufficiency on Drug Metabolism	331
13.3.2	Pharmacokinetic Changes in Hepatic Insufficiency	332
13.3.3	Effect of Liver Diseases on Pharmacokinetics of Drugs	333
13.4	Dosing Algorithms in Clinical Practice	334
13.4.1	Drug Selection	335
13.4.2	Dosing Adjustments	336
13.4.3	Pharmacokinetic Considerations	336
13.5	Drug Disposition and Factors That Influence Drug Disposition	336
13.6	Major Classes of Drugs and Hepatic Insufficiency	337
13.6.1	Anticoagulants	337
13.6.2	Antibiotics	338
13.6.3	Analgesics	338

13.6.4	Anticonvulsants	338
13.6.5	Antidepressants	339
13.6.6	Antiretrovirals	339
13.7	Cases Demonstrating Application of Dosing Algorithms	339
13.7.1	Case 1: Warfarin for Anticoagulation	339
13.7.1.1	The Use of Warfarin in a Patient with Hereditary Bleeding Disorder	339
13.7.1.2	Dosing Algorithm of Warfarin	340
13.7.2	Case 2: Acetaminophen for Pain Management	340
13.7.2.1	Dosing Algorithm for Paracetamol and Other Cytochrome p450 Enzyme-inducing Drugs in Hepatic Insufficiency Using Child-Pugh Score	341
13.7.3	Case 3: Valproic Acid for Seizure Control	341
13.7.4	Case 4: Metronidazole for Infection	342
13.7.5	Case 5: Efavirenz for HIV Treatment	342
13.8	Limitations of Current Dosing Strategies	342
13.9	Conclusion and Future Perspectives	343
13.9.1	Emerging Technologies and Precision Medicine	343
13.9.2	Potential Impact of Pharmacogenomics	344
13.9.3	Areas of Research Interest	344
	References	345

14 Drug Disposition in Geriatrics 349

Ali Karimi, Samuel Cockey, Millena Levin, Teresa Travnicek, Nishanth Chalasani, and Charles Preuss

14.1	Introduction	349
14.2	Absorption	351
14.3	Distribution	352
14.4	Metabolism	354
14.5	Excretion	356
14.6	Hepatic	360
14.7	Renal	361
14.8	Cardiac	363
14.9	Sex Differences	363
14.10	Psychoactive Drugs	365
14.11	Anesthesiology Drugs	366
14.12	Drug Interactions	367
14.13	Drug Side Effects	368
14.14	Conclusion	371
	Abbreviations	372
	References	373

15	Considerations and Regulatory Affairs for Clinical Research in Special Populations	377
	<i>Stephanie Leigh, Maxine Turner, and Goonaseelan C. Pillai</i>	
15.1	Introduction	377
15.2	Regulatory Frameworks for Clinical Research in Special Populations	378
15.2.1	The Historical Evolution of Regulatory Frameworks for Special Population Research	378
15.2.2	Current Global Regulatory Frameworks for Special Population Research	380
15.2.3	Current Regional Regulations Concerning Clinical Research Involving Special Populations	382
15.2.3.1	The United States: Food and Drug Regulatory Authority (US FDA)	382
15.2.3.2	Europe: European Medicines Agency (EMA)	383
15.2.3.3	The United Kingdom: The Medicines and Healthcare Products Regulatory Agency (MHRA)	383
15.2.3.4	Australia: The Therapeutic Goods Administration (TGA)	384
15.2.3.5	Brazil: National Health Surveillance Agency (ANVISA)	385
15.2.3.6	India: Central Drugs Standard Control Organization (CDSCO)	387
15.2.3.7	China: National Medical Products Administration (NMPA)	388
15.2.3.8	South Africa: The South African Health Products Regulatory Authority (SAHPRA)	389
15.2.4	Holistic Analysis of Regional Regulations Concerning Clinical Research Involving Special Populations	391
15.3	Key Considerations for Clinical Trials in Special Population Groups	392
15.3.1	Pediatric Population Groups	392
15.3.1.1	Regulatory Guidelines Governing Pediatric Clinical Research	392
15.3.2	Regional Legislations Governing Clinical Research in Pediatric Populations	393
15.3.2.1	The United States: Food and Drug Regulatory Authority (US FDA)	393
15.3.2.2	Europe: European Medicines Agency (EMA)	395
15.3.2.3	The United Kingdom: The Medicines and Healthcare Products Regulatory Agency (MHRA)	396
15.3.2.4	India: Central Drugs Standard Control Organization (CDSCO)	396
15.3.2.5	Other Global Jurisdictions	397
15.3.3	Holistic Analysis of Regional Regulations Concerning Clinical Research Involving Pediatric Populations	398

15.3.4	Ethical Considerations for Clinical Research in Pediatric Populations	398
15.3.4.1	Assent and Informed Consent	399
15.3.4.2	Participant Recruitment	402
15.4	Pregnant Population Groups	403
15.4.1	Historical Exclusion of Pregnant Persons in Clinical Research	403
15.4.2	Regulatory Guidelines Governing Clinical Research in Pregnant Persons	404
15.4.3	Regional Legislations Governing Clinical Research in Pregnant Persons	406
15.4.3.1	The United States: Food and Drug Regulatory Authority (US FDA)	406
15.4.3.2	Europe: European Medicines Agency (EMA)	406
15.4.3.3	Australia: The Therapeutic Goods Administration (TGA)	407
15.4.3.4	Brazil: National Health Surveillance Agency (ANVISA)	407
15.4.3.5	India: Central Drugs Standard Control Organization (CDSCO)	408
15.4.3.6	China: National Medical Products Administration (NMPA)	409
15.4.4	Challenges and Barriers to Clinical Research in Pregnant Persons	409
15.5	Geriatric Populations	410
15.5.1	Key Regulatory Guidelines Governing Geriatric Clinical Research	411
15.5.2	Regional Legislations Governing Clinical Research in Geriatric Populations	412
15.5.2.1	The United States: Food and Drug Regulatory Authority (US FDA)	412
15.5.2.2	Europe: European Medicines Agency (EMA)	414
15.5.2.3	The United Kingdom: The Medicines and Healthcare Products Regulatory Agency (MHRA)	415
15.5.2.4	India: Central Drugs Standard Control Organization (CDSCO)	416
15.5.2.5	Other Global Jurisdictions	417
15.5.3	Challenges and Barriers to Clinical Research in Geriatric Populations	417
15.6	Critical Care	417
15.6.1	Key Regulatory Guidelines Governing Critical Care Clinical Research	418
15.6.2	Regional Legislations Governing Clinical Research in Critical Care Populations	418
15.6.2.1	The United States: Food and Drug Regulatory Authority (US FDA)	418
15.6.2.2	Europe: European Medicines Agency (EMA)	420

- 15.6.2.3 The United Kingdom: The Medicines and Healthcare Products Regulatory Agency (MHRA) 420
- 15.6.2.4 India: Central Drugs Standard Control Organization (CDSCO) 421
- 15.6.2.5 Other Global Jurisdictions 421
- 15.6.3 Challenges and Barriers to Clinical Research in Critical Care Populations 422
- 15.7 Summary Points 422
- 15.7.1 Regulatory Guidelines 422
- 15.7.2 Ethical Considerations 423
- 15.7.3 Participant Recruitment 423
- 15.8 Conclusion 423
- References 424

Index 435

About the Editors

Seth Kwabena Amponsah is an associate professor and former head of Department of Medical Pharmacology, University of Ghana Medical School. He has an MPhil and PhD in pharmacology. He has had postdoctoral fellowships under BANGA-Africa Project and BSU III (DANIDA—Denmark). He has over 13 years' experience in teaching and research. He teaches students in the medical school, school of pharmacy, school of nursing and midwifery, and school of biomedical and allied health sciences. His research focus includes clinical pharmacology (infectious disease and antimicrobial stewardship): prudent use of antimicrobials, antimicrobial level monitoring, and efficacy of antimicrobials in patients. He also has experience in population pharmacokinetic modeling, non-compartment pharmacokinetic estimation, and pharmacokinetic evaluation of new drug formulations. He has supervised several undergraduate and postgraduate students. He has published over 60 research articles, 3 books, 20 book chapters and several conference abstracts. He is an academic editor for PLOS One and an associate editor for Pan African Medical Journal.

Yashwant V. Pathak has over 16 years of versatile administrative experience in an Institution of Higher education as dean (and over 30 years as faculty and as a researcher in higher education after his PhD). Presently holds the position for associate dean for faculty affairs and tenured professor of pharmaceutical sciences. He is an internationally recognized scholar, researcher, and educator in the areas of health care education, nanotechnology, drug delivery systems, and nutraceuticals. He has received many international and national awards including four Fulbright Fellowships, Endeavour Executive Fellowship by Australian Government, four outstanding faculty awards, and he was selected as fellow of American Association for Advancement of Science (AAAS) in 2021. He has published over 350 research publications, reviews, and chapters in various books. He has edited over 60 books in various fields including nanotechnology,

nutraceuticals, conflict management, and cultural studies. He is also actively involved many nonprofit organizations, to mention a few, Hindu Swayamsevak Sangh, USA, Sewa International USA, International accreditation council for Dharma Schools and Colleges, International commission for Human rights and religious freedom, and Uberoi Foundation for religious studies, among others.

List of Contributors

Fried A. Abilba

Department of Paediatric and Child
Health Pharmacy
Tamale Teaching Hospital
Tamale
Ghana

James A. Akingbasote

Regulatory Toxicologist
London, Ontario
Canada

Raphael N. Alolga

State Key Laboratory of Natural
Medicines, Department of
Pharmacognosy
China Pharmaceutical University
Nanjing
China

and

Clinical Metabolomics Center
Department of Pharmacognosy
China Pharmaceutical University
Nanjing
China

Emmanuel B. Amofo

Department of Pharmaceutical
Sciences
North Dakota State University
Fargo, ND
USA

Seth K. Amponsah

Department of Medical Pharmacology
University of Ghana Medical School
Accra
Ghana

Aparna Anandan

Translational Research Laboratory
Department of Biotechnology
Bharathiar University
Coimbatore, Tamil Nadu
India

Unais Annenkottil

Translational Research Laboratory
Department of Biotechnology
Bharathiar University
Coimbatore
Tamil Nadu, India

Vishnu P. Athilingam

Translational Research Laboratory
Department of Biotechnology
Bharathiar University
Coimbatore, Tamil Nadu
India

Michael M. Attah

Division of Clinical Pharmacology
Indiana University School of
Medicine
Indianapolis, IN
USA

and

Department of Pharmacy Practice
College of Pharmacy
Purdue University
West Lafayette, IN
USA

Jacob A. Ayembilla

Department of Science Laboratory
Technology
Accra Technical University
Accra
Ghana

Stefanos Belavilas

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Gabriella Blanco

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Alexandra Burton

Nationwide Children's Hospital
Columbus, OH
USA

Nishanth Chalasani

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Samuel Cockey

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Justin Cole

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Dominique Cook

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Aparoop Das

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

Dibyajyoti Das

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India
and

Pratiksha Institute of Pharmaceutical
Science
Guwahati, Assam
India

Mansa Fredua-Agyeman

Department of Pharmaceutics and
Microbiology, School of Pharmacy
University of Ghana
Accra
Ghana

Anuradha K. Gajjar

Department of Pharmaceutical
Chemistry
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Urvashee Gogoi

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

David Gyamfi

Department of Pharmaceutical
Sciences
North Dakota State University
Fargo, ND
USA

Arindam Halder

Sun Pharmaceutical Industries Ltd.
Vadodara, Gujarat
India

Rana Hanna

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Kartik Hariharan

Sun Pharmaceutical Industries Ltd.
Vadodara, Gujarat
India

Elora Hilmas

Nationwide Children's Hospital
Columbus, OH
USA

Md Ariful Islam

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

Partha P. Kalita

Faculty of Science
Assam down town University
Guwahati, Assam
India

Ali Karimi

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Ajay J. Khopade

Sun Pharmaceutical Industries Ltd.
Vadodara, Gujarat
India

Seema Kohli

Pharmacy Department
K N Polytechnic College
Jabalpur, MP
India

Awo A. Kwapong

Department of Pharmaceutics
and Microbiology, School of
Pharmacy
University of Ghana
Accra
Ghana

Stephanie Leigh

Department of Pharmacy and
Pharmacology, Faculty of Health
Sciences
University of the Witwatersrand
Johannesburg
South Africa

Millena Levin

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Deborah Liaw

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Mahesh P. More

Novel Formulation Laboratory
Sekkei Bio Pvt Ltd.
Bangalore, KA
India

Chinenye E. Muolokwu

Department of Pharmaceutical
Sciences, School of Pharmacy
College of Health and Human
Sciences
North Dakota State University
Fargo, ND
USA

Sarah Nestler

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Viswanadha V. Padma

Translational Research
Laboratory, Department of
Biotechnology
Bharathiar University
Coimbatore, Tamil Nadu
India

Amitkumar K. Patel

Saffron Health LLC
East Brunswick, NJ
USA

Jayvadan K. Patel

Vie Saine Pharma LLC
Sheridan, WY
USA

Kashyap M. Patel

Department of Pharmaceutics
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Manish P. Patel

Department of Pharmaceutics
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Vivek Patel

Apex professional University
Pasighat, Arunachal Pradesh
India

and

Sun Pharmaceutical Industries Ltd.
Vadodara, Gujarat
India

Kalyani Pathak

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

Manash P. Pathak

Faculty of Pharmaceutical Sciences
Assam Down Town University
Guwahati, Assam
India

Yahwant V. Pathak

USF Health Taneja College of
Pharmacy
University of South Florida
Tampa, FL
USA

Goonaseelan C. Pillai

Division of Clinical Pharmacology
University of Cape Town
Rondebosch
South Africa

and

CP+ Associates GmbH
Basel
Switzerland

Amruta Potdar

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Pallab Pramanik

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

Charles Preuss

Department of Molecular
Pharmacology & Physiology
University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Jon J. Sahariah

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

Riya Saikia

Department of Pharmaceutical
Sciences
Dibrugarh University
Dibrugarh, Assam
India

Surovi Saikia

Translational Research Laboratory
Department of Biotechnology
Bharathiar University
Coimbatore, Tamil Nadu
India

Dhruv Shah

Sun Pharmaceutical Industries Ltd.
Vadodara, Gujarat
India

Ellen Si

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Ankita A. Singh

Pharmacy Department
K N Polytechnic College
Jabalpur, MP
India

Sandra K. Szlapinski

Regulatory Toxicologist
London, Ontario
Canada

Rahul S. Tade

H R Patel Institute of Pharmaceutical
Education and Research
Dhule, MS
India

Benjamin Tagoe

Department of Pharmaceutical
Sciences, School of Pharmacy
College of Health and Human
Sciences
North Dakota State University
Fargo, ND
USA

Teresa Travnicek

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Jacob Treanor

University of South Florida Morsani
College of Medicine
Tampa, FL
USA

Maxine Turner

Department of Pharmacy and
Pharmacology, Faculty of Health
Sciences
University of the Witwatersrand
Johannesburg
South Africa

Shakil Z. Vhora

Department of Pharmaceutics
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Kyle Weston

Regulatory Toxicologist
Toronto, Ontario
Canada

Yelena Wu

Nationwide Children's Hospital
Columbus, OH
USA